| Revenue growth | Consolidated +29%; standalone Q2 +9.3%, H1 +9.0% |
|---|---|
| Margins | Q2 standalone EBITDA 22.7% (-151bps); gross margin +70bps |
| Demand visibility | MR productivity +10%; 7 of top 10 brands outgrew market |
| Management confidence | Confident of Q3 acceleration and Mission 2028 target |
Growth
Standalone H1 revenue +9.0%, EBITDA +11.3%, PAT +10.3%. Q2 gross margin +70bps to 64.1%; Q2 EBITDA +2.5%, PAT flat.
Outlook
Guides Q3FY27 quarterly revenue above ₹1,000 Mn; reiterates Mission 2028 target of ₹5,000 Mn annual revenue. Pursuing more acquisitions; no capex guided.
Risks
Q2 investment ahead of growth cut EBITDA margin 151 bps YoY. Aequitas margin reset impact visible only from Q4FY27.
Last quarter's promises, checked
Delivered
- Aequitas 85% for Rs20.8 Cr → ₹208 Mn cash (= BEAT)
Partly delivered
- Growth to accelerate beyond Q1 9% → Q2 standalone +9.3%, H1 +9.0% (= PARTIAL)
Missed
- Productivity-led margin expansion, Q1 EBITDA margin 23%+ → Q2 22.7%, −151bps YoY (= MISS)
- Q1 gross margin 65%+ as trend → Q2 64.1% (= MISS)
- Aequitas numbers 'in next two quarters' → margin reset visible only Q4FY27 (= MISS)
Investor Presentation filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹230.96
- Market cap
- ₹1,523 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 33.5×Sector 46.1×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 101,825 equity shares upon the exercise of employee stock options. This issuance expands the company's paid-up share capital.